231 related articles for article (PubMed ID: 20627636)
1. The staging and treatment of multicentric high-grade lymphoma in dogs: a review of recent developments and future prospects.
Marconato L
Vet J; 2011 Apr; 188(1):34-8. PubMed ID: 20627636
[TBL] [Abstract][Full Text] [Related]
2. Principles of treatment for canine lymphoma.
Ettinger SN
Clin Tech Small Anim Pract; 2003 May; 18(2):92-7. PubMed ID: 12831068
[TBL] [Abstract][Full Text] [Related]
3. Autologous marrow transplantation as consolidation therapy for canine lymphoma: efficacy and toxicity of various regimens of total body irradiation.
Deeg HJ; Appelbaum FR; Weiden PL; Hackman RC; Graham TC; Storb RC
Am J Vet Res; 1985 Sep; 46(9):2016-8. PubMed ID: 3901841
[TBL] [Abstract][Full Text] [Related]
4. Thirteen-week dose-intensifying simultaneous combination chemotherapy protocol for malignant lymphoma in dogs.
Zenker I; Meichner K; Steinle K; Kessler M; Hirschberger J
Vet Rec; 2010 Nov; 167(19):744-8. PubMed ID: 21257510
[TBL] [Abstract][Full Text] [Related]
5. Predictors of long-term survival in dogs with high-grade multicentric lymphoma.
Marconato L; Stefanello D; Valenti P; Bonfanti U; Comazzi S; Roccabianca P; Caniatti M; Romanelli G; Massari F; Zini E
J Am Vet Med Assoc; 2011 Feb; 238(4):480-5. PubMed ID: 21320018
[TBL] [Abstract][Full Text] [Related]
6. Cytosine arabinoside in addition to VCAA-based protocols for the treatment of canine lymphoma with bone marrow involvement: does it make the difference?
Marconato L; Bonfanti U; Stefanello D; Lorenzo MR; Romanelli G; Comazzi S; Zini E
Vet Comp Oncol; 2008 Jun; 6(2):80-9. PubMed ID: 19178667
[TBL] [Abstract][Full Text] [Related]
7. Mechlorethamine, procarbazine and prednisone for the treatment of resistant lymphoma in dogs.
Northrup NC; Gieger TL; Kosarek CE; Saba CF; LeRoy BE; Wall TM; Hume KR; Childress MO; Keys DA
Vet Comp Oncol; 2009 Mar; 7(1):38-44. PubMed ID: 19222829
[TBL] [Abstract][Full Text] [Related]
8. Canine lymphomas: association of classification type, disease stage, tumor subtype, mitotic rate, and treatment with survival.
Valli VE; Kass PH; San Myint M; Scott F
Vet Pathol; 2013 Sep; 50(5):738-48. PubMed ID: 23444036
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma.
Simon D; Moreno SN; Hirschberger J; Moritz A; Kohn B; Neumann S; Jurina K; Scharvogel S; Schwedes C; Reinacher M; Beyerbach M; Nolte I
J Am Vet Med Assoc; 2008 Mar; 232(6):879-85. PubMed ID: 18341445
[TBL] [Abstract][Full Text] [Related]
10. Histologic classification as an indication of therapeutic response in malignant lymphoma of dogs.
Gray KN; Raulston GL; Gleiser CA; Jardine JH
J Am Vet Med Assoc; 1984 Apr; 184(7):814-7. PubMed ID: 6725115
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic assessment of canine lymphoma: implications for treatment.
Bienzle D; Vernau W
Clin Lab Med; 2011 Mar; 31(1):21-39. PubMed ID: 21295720
[TBL] [Abstract][Full Text] [Related]
12. Primary malignant lymphoma of the urinary bladder in a dog: longterm remission following treatment with radiation and chemotherapy.
Kessler M; Kandel-Tschiederer B; Pfleghaar S; Tassani-Prell M
Schweiz Arch Tierheilkd; 2008 Nov; 150(11):565-9. PubMed ID: 18979422
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of leukemic blood and bone marrow in dogs with multicentric lymphoma.
Raskin RE; Krehbiel JD
J Am Vet Med Assoc; 1989 May; 194(10):1427-9. PubMed ID: 2470709
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin.
Valerius KD; Ogilvie GK; Fettman MJ; Walton JA; Richardson K; Powers BE; McNiel EA; Rogers QR
J Am Vet Med Assoc; 1999 Feb; 214(3):353-6. PubMed ID: 10023395
[TBL] [Abstract][Full Text] [Related]
15. Principles of treatment for feline lymphoma.
Ettinger SN
Clin Tech Small Anim Pract; 2003 May; 18(2):98-102. PubMed ID: 12831069
[TBL] [Abstract][Full Text] [Related]
16. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995).
Valerius KD; Ogilvie GK; Mallinckrodt CH; Getzy DM
J Am Vet Med Assoc; 1997 Feb; 210(4):512-6. PubMed ID: 9040837
[TBL] [Abstract][Full Text] [Related]
18. [Recent progress in the treatment of malignant lymphoma].
Ogura M
Gan To Kagaku Ryoho; 2001 Sep; 28(9):1213-35. PubMed ID: 11579632
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007).
Flory AB; Rassnick KM; Erb HN; Garrett LD; Northrup NC; Selting KA; Phillips BS; Locke JE; Chretin JD
J Am Vet Med Assoc; 2011 Feb; 238(4):501-6. PubMed ID: 21320021
[TBL] [Abstract][Full Text] [Related]
20. Intralymphatic autochthonous tumor cell vaccine in canine lymphoma.
Jeglum KA; Young KM; Barnsley K; Whereat A; McGrath D; Hutson C
J Biol Response Mod; 1986 Apr; 5(2):168-75. PubMed ID: 3734843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
